The use of α-adrenoceptor antagonists in lower urinary tract disease

REFERENCES

• MICHEL MC, KENNY BA, SCHWINN DA: Classification of aradrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacy]. (1995) 352:1–10.
   PubMed Web of Science ®Google Scholar
• FORD APDW, ARREDONDO NF, BLUE DR et al: RS-17053 0\l- [242-Cyclopropylmethoxyphenoxy)ethy11-5-chloro-a,a-dimethy1-1H-indole-3-ethanamine hydrochloride), a selective abk-adrenoceptor antagonist, displays low affinity for functional aradrenoceptors in human prostate: Implications for adrenoceptor classification. Mal Pharmacy] (1996) 49:209–215.
   PubMed Web of Science ®Google Scholar
• CHANG DJ, CHANG TK, YAMANISHI SS et al: Molecular cloning, genomic characterisation and expression of novel human aiKadrenoceptor isoforms. FEBS Letters (1998) 422:279–283.
   PubMed Web of Science ®Google Scholar
• FORD APDW, DANIELS DV, CHANG DJ etal.: Pharmacological pleiotropism of the human recombinant aucadrenoceptor: implications for aradrenoceptor classification. Br j Pharmacy] (1997) 121:1127–1135.
   Google Scholar
• DANIELS DV, GEVER JR, JASPER JR et al.: Human cloned aucadrenoceptor isoforms display aw-adrenoceptor pharmacology in functional studies. Eur. Pharmacy]. (1999) 370:337–343.
   PubMed Web of Science ®Google Scholar
• BERRY SJ, COFFEY DS, WALSH PC et al.: The development of human benign prostatic hyperplasia with age. j Ural. (1984) 132:474–479.
   PubMed Web of Science ®Google Scholar
• CAINE M, RAZ S, ZEIGLER M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br .j Ural. (1975) 47:193–202.
   PubMedGoogle Scholar
• FURUYA S, KUMAMOTO Y, YOKOYAMA E et al.: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hyperplasia. j Ural. (1982) 128:836–839.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, DAVIS BJ & CHESS-WILLIAMS R: Prostate-vascular selectivity of tamsulosin, doxazosin and alfuzosin. BJU Irk (2000) 86\(Suppl. 3):98.
   Google Scholar
• CAINE M, PERLBERG S, MERETYK S: A placebo-controlled double-blind study of the effects of phenoxybenzamine in benign prostatic obstruction. Br j Ural. (1978) 50:551–554.
   PubMedGoogle Scholar
• DJAVAN B, MARBERGER M: A meta-analysis on the efficacy and tolerability of aradrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Ural. (1999) 36:1-13. ••A comparison of the efficacy andtolerability of the main aradrenoceptor antagonists currently in use.
   Google Scholar
• LEFEVRE-BORG F, O'CONNOR S, SCHOEMAKER H et al.: Alfuzosin, a selective alphal-adrenoceptor antagonist in the lower urinary tract. Br I Pharmacy]. (1993) 109:1282-1289. •Evidence suggesting that the uroselectivity of alfuzosin may be due to the drug being concentrated in the prostate compared with the plasma.
   Google Scholar
• MARSHALL I, BURT RP, CHAPPLE CR: Noradrenaline contractions of human prostate mediated by("--1C-)adrenoceptor subtype. Br I Pharmacal (1995) 115:781–786.
   PubMed Web of Science ®Google Scholar
• HATANO A, TAKAHASHI H, TAMAKI M: Pharmacological evidence of distinct al-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br I Pharmacal (1994) 113:723–728.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, BURT RP MARSHALL I: aradrenoceptor subtypes in the human prostate and inferior epigastric artery. Neural. Uradyn. (1991) 10:306–308.
   Google Scholar
• NOBLE AJ, CHESS-WILLIAMS R, COULDWELL C et al.: The effects of tamsulosin, a high affinity antagonist at functional alp,- and amradrenoceptor subtypes. Br. J. Pharm. (1997) 120:231-238. •Evidence that tamsulosin discriminates between functional aradrenoceptor subtypes.
   Google Scholar
• CHESS-WILLIAMS R, CHAPPLE CR, VERFURTH E NOBLE AJ, COULDWELL CJ, MICHEL MC: The effects of SB 216469, an antagonist which discriminates between the aiKadrenoceptor and the human prostatic aradrenoceptor. Br. J. Pharmacy]. (1996) 119:1093–1100.
   PubMed Web of Science ®Google Scholar
• British National Formulary 41, Phamaceutical Press, PO Box 151, Oxon, UK. (2001).
   Google Scholar
• TERPENING C, GUMS JG, GRAUER K: Management of hypertension. Expert Opin. Pharmacather. (1999) 1(1):71–80.
   PubMedGoogle Scholar
• XIN X, YANG N, ECKHART AD et al: amradrenergic receptors and mitogen-activated protein kinase mediate increased protein synthesis by arterial smooth muscle. Mal. Pharmacy]. (1997) 51:764–775.
   PubMed Web of Science ®Google Scholar
• NISHIO E, WATANABE Y: Troglitazone inhibits a1adrenoceptor-induced DNA synthesis in vascular smooth muscle cells. Euri Pharmacal (1999) 374:127–135.
   PubMed Web of Science ®Google Scholar
• KYPRIANOU N, LITVAK JP, BORKOWSKI A etal.: Induction of prostatic apoptosis by doxazosin in benign prostatic hyperplasia. I Ural. (1998) 159:1810–1815.
   Google Scholar
• CHON JK, BORKOWSKI A, PARTIN AW: aradrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia, Ural. (1999) 161:2002–2008.
   Google Scholar
• MCCONNELL JD, BRUSKEWITZ R, WALSH P et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl. Med. (1998) 338:557–563.
   PubMed Web of Science ®Google Scholar
• LUKACS B, DOUBLET JD, CIOFFU Cetal.: Incidence of acute urinary retention, surgery and drop-out rates in 3228 BPH patients treated 3 years with alfuzosin. Eur. Ural. (1999) 35\(Suppl. 2):77–82.
   Google Scholar
• SCHULMAN CC, LOCK TMTW, BUZELIN JM: Tamsulosin: 3-year follow up of efficacy & safety in 516 patients with LUTS suggestive of BPO. I Ural. (1998) 159\(Suppl. 5):256–261.
   Google Scholar
• JARDIN A, BENSADOUN H, DELAUCHE-CAVALLIER MC etal. & THE BPHALF GROUP: Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey. Br Ural. (1994) 74:579–584.
   Google Scholar
• LEPOR H, NIEDER A, FESER J et al: Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology (1997) 49: 476–480.
   PubMed Web of Science ®Google Scholar
• HEIMBACH D, MULLER SC: Treatment of prostatic hyperplasia with alphal-adrenoceptor antagonists. Uralage Ausgabe A. (1997) 36:18–34.
   PubMedGoogle Scholar
• MALLOY BJ, PRICE DT, PRICE RR: al-adrenergic receptor subtypes in human detrusor. I Ural. (1998) 160:937–943.
   Google Scholar
• SMITH DJ, CHAPPLE CR: In vitro response of human bladder smooth muscle in unstable obstructed male bladders: a study of pathophysiological status. Neuraural Uradyn. (1994) 13:414–415.
   Google Scholar
• SMITH MS, SCHAMBRA UB, WILSON KH et al.: aradrenergic receptors in human spinal cord: specific localized expression of mRNA encoding aradrenergic receptor subtypes at four distinct levels. Mal Brain Res. (1999) 63:254–261.
   Web of Science ®Google Scholar
• ISHIZUKA 0, PERSSON K, MATTIASSON A etal.: Micturition in conscious rats with and without bladder outlet obstruction: role of spinal al-adrenoceptors. Br I Pharmacal (1996) 117:962–966.
   Google Scholar